Cytonics Corporation

Cytonics Corporation is a clinical-stage biotechnology company focused on developing first-in-class biologic therapies and diagnostics for musculoskeletal diseases, primarily osteoarthritis (OA). The company's core platform leverages the therapeutic potential of Alpha-2-Macroglobulin (A2M), a naturally occurring blood protein that acts as a broad-spectrum protease inhibitor to prevent cartilage degradation. Unlike traditional therapies that focus on palliative pain management, Cytonics' lead candidate, CYT-108, is an engineered 'super-variant' of A2M designed to halt or potentially reverse the progression of OA by neutralizing the destructive enzymes (proteases) that drive the disease. The company differentiates itself through a capital-efficient, grassroots funding model, primarily raising capital through equity crowdfunding (Regulation A+) from retail investors rather than traditional venture capital.